Triamcinolone acetonide (TA) is a corticosteroid that has been widely used to treat ocular inflammation. However, due to the physicochemical properties of TA, this drug has low solubility and permeability. This study aims to improve the solubility of TA and promote better ocular absorption through solid dispersion (SD) formulation with the solvent evaporation method incorporated into in situ gel. The SD-TA was characterized by FTIR, XRD, and SEM to confirm physicochemical modifications that support enhanced solubility. The most optimal SD-TA will then be combined into an in situ gel base with a composition of poloxamer, HPMC, and HPC. The resulting in situ gel exhibited desirable physical properties, remained isotonic with lacrimal fluid, and showed no signs of toxicity. Moreover, the system achieved prolonged ocular retention, with 3.15 ± 0.15 mg of TA retained on the ocular membrane after 24 h, indicating strong potential for sustained local therapeutic effect. In conclusion, this study successfully developed a new TA delivery approach that enhances solubility, prolongs ocular residence time, and improves local anti-inflammatory efficacy. Further in vivo studies and long-term stability assessments are recommended to support clinical translation.
WongCWMetselaarJMStormG, et al.A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. Br J Ophthalmol2021; 105: 1617–1622.
2.
XingYZhuLZhangK, et al.Nanodelivery of triamcinolone acetonide with PLGA-chitosan nanoparticles for the treatment of ocular inflammation. Artif Cells, Nanomed Biotechnol2021; 49: 308–316.
3.
LinPSuhlerEBRosenbaumJT. The future of uveitis treatment. Ophthalmology2014; 121: 365–376.
4.
MorrisonVKohHChengL, et al.Intravitreal toxicity of the Kenalog vehicle (Benzyl alcohol) in rabbits. Retina2006; 26: 339–344.
5.
JonasJBKreissigIDegenringR. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol2003; 87: 24–27.
6.
RupenthalIDGreenCRAlanyRG. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release. Int J Pharm2011; 411: 69–77.
7.
TatkeADudhipalaNJangaKY, et al.In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials2018; 9: 33.
8.
KhanMSRaviPRDhavanDS. Design, optimization, in vitro and in vivo evaluation of triamcinolone acetonide nanocrystals loaded in situ gel for topical ocular delivery. Colloids Surf B Biointerfaces2023; 231: 113539.
9.
FormicaMLAwde AlfonsoHGParedesAJ, et al.Development of triamcinolone acetonide nanocrystals for ocular administration. Pharmaceutics2023; 15: 683.
10.
GigliobiancoMRCasadidioCCensiR, et al.Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics2018; 10: 134.
11.
PatelACholkarKAgrahariV, et al.Ocular drug delivery systems: an overview. World J Pharmacol2013; 2: 47–64.
12.
TundisiLLMostaçoGBCarricondoPC, et al.Hydroxypropyl methylcellulose: physicochemical properties and ocular drug delivery formulations. Eur J Pharm Sci2021; 159: 105736.
13.
GamaleroLSimoniniGFerraraG, et al.Evidence-based treatment for uveitis. Isr Med Assoc J2019; 21: 475–479.
14.
ChanNSWChoiJCheungCMG. Pediatric uveitis. Asia Pac J Ophthalmol2018; 7: 192–199.
15.
TatkeADudhipalaNJangaKY, et al. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials2019; 9.
16.
RahmanZZidanASKhanMA. Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods. AAPS J2010; 12: 158–170.
17.
PermanaADParedesAJVolpe-ZanuttoF, et al.Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Eur J Pharm Biopharm2020; 154: 50–61.
18.
PermanaADUtomoEPratamaMR, et al.Bioadhesive-thermosensitive in situ vaginal gel of the gel flake-solid dispersion of itraconazole for enhanced antifungal activity in the treatment of vaginal candidiasis. ACS Appl Mater Interfaces2021; 13: 18128–18141.
19.
ZhangYHuoMZhouJ, et al.DDSolver: an Add-In program for modeling and comparison of drug dissolution profiles. AAPS J2010; 12: 263–271.
20.
KhattabAMarzokSIbrahimM. Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of latanoprost: antiglaucoma efficacy and stability approaches. J Drug Deliv Sci Technol2019; 53: 101134.
21.
SapinoSPeiraEChirioD, et al.Thermosensitive nanocomposite hydrogels for intravitreal delivery of cefuroxime. Nanomaterials2019; 9: 1461.
22.
BotrosSRHusseinAKMansourHF. A novel nanoemulsion intermediate gel as a promising approach for delivery of itraconazole: design, in vitro and Ex vivo appraisal. AAPS PharmSciTech2020; 21: 272–274.
23.
SukmawatyMSartiniPADMudjahidM, et al. Lipid complex-itraconazole in thermosensitive mucoadhesive vaginal gel to enhance the effectiveness of therapy for vulvovaginal candidiasis: formulation, optimization, characterization, and Ex vivo evaluation. J Pharm Innov2023; 18.
24.
Nurul Fitri MarzamanASartiniMMMudjahidM, et al.Development of chloramphenicol whey protein-based microparticles incorporated into thermoresponsive in situ hydrogels for improved wound healing treatment. Int J Pharm2022; 628: 122323.
25.
WangYJiangSWangH, et al.A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS One2017; 12: e0189478.
26.
EnggiCKIsaHTSulistiawatiS, et al.Development of thermosensitive and mucoadhesive gels of cabotegravir for enhanced permeation and retention profiles in vaginal tissue: a proof of concept study. Int J Pharm2021; 609: 121182.
27.
KoiralaSNepalPGhimireG, et al.Formulation and evaluation of mucoadhesive buccal tablets of aceclofenac. Heliyon2021; 7: e06439.
28.
MirMPermanaADTekkoIA, et al.Microneedle liquid injection system assisted delivery of infection responsive nanoparticles: a promising approach for enhanced site-specific delivery of carvacrol against polymicrobial biofilms-infected wounds. Int J Pharm2020; 587: 119643.
29.
European Medicine Agency. ICH guideline Q14 on analytical procedure development. 2022.
30.
TatkeADudhipalaNJangaKY, et al. Melt-cast films significantly enhance triamcinolone acetonide delivery to the deeper ocular tissues. Pharmaceutics2019; 11.
31.
VerheyenSAugustijnsPKingetR, et al.Melting behavior of pure polyethylene glycol 6000 and polyethylene glycol 6000 in solid dispersions containing diazepam or temazepam: a DSC study. Thermochim Acta2001; 380: 153–164.
32.
SerajuddinATM. Solid dispersion of poorly water‐soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci1999; 88: 1058–1066.
33.
LeunerCDressmanJ. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm2000; 50: 47–60.
34.
SurawaseRKBahetiKG. Solid dispersion by fluidized bed processing: a platform for enhancement of dissolution rate of simvastatin poorly water-soluble drug. J Pharm Res Int2021; 33 (Issue 42A): 32–43.
35.
RamtekeKHDighePAKharatAR, et al.Mathematical models of drug dissolution: a review. Scholars Acad J Pharm2014; 3: 388–396.
36.
PintoFCHda Silva-Cunha JuniorAOréficeRL, et al.Controlled release of triamcinolone acetonide from polyurethane implantable devices: application for inhibition of inflammatory-angiogenesis. J Mater Sci Mater Med2012; 23: 1431–1445.
37.
García-MillánEQuintáns-CarballoMOtero-EspinarFJ. Solid-state characterization of triamcinolone acetonide nanosuspensiones by X-ray spectroscopy, ATR fourier transforms infrared spectroscopy and differential scanning calorimetry analysis. Data Brief2017; 15: 133–137.
38.
SabzevariAAdibkiaKHashemiH, et al.Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. Eur J Pharm Biopharm2013; 84: 63–71.
39.
YousafAMMalikURShahzadY, et al.Silymarin-laden PVP-PEG polymeric composite for enhanced aqueous solubility and dissolution rate: preparation and in vitro characterization. J Pharm Anal2019; 9: 34–39.
40.
HuangYDaiW-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B2014; 4: 18–25.
41.
BudimanAAulifaDL. A comparative study of the pharmaceutical properties between amorphous drugs loaded-mesoporous silica and pure amorphous drugs prepared by solvent evaporation. Pharmaceuticals2022; 15: 730.
42.
TangJBaoJShiX, et al.Preparation, optimisation, and in Vitro–in vivo evaluation of febuxostat ternary solid dispersion. J Microencapsul2018; 35: 454–466.
43.
DelMonteDWKimT. Anatomy and physiology of the cornea. J Cataract Refract Surg2011; 37: 588–598.
44.
DumortierGGrossiordJLAgnelyF, et al.A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res2006; 23: 2709–2728.
45.
SaskiWShahSG. Availability of drugs in the presence of surface-active agents I critical micelle concentrations of some. Oxyethylene Oxypropylene Polymers1965; 54: 71–74.
46.
DürigTKaranK. Binders in wet granulation. In: Handbook of pharmaceutical wet granulation. Elsevier, 2019, pp. 317–349.
47.
CarvalhoFCBruschiMLEvangelistaRC, et al.Mucoadhesive drug delivery systems. Braz J Pharm Sci2010; 46: 1–17.
48.
SmartJ. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev2005; 57: 1556–1568.
49.
Diaz-SalmeronRToussaintBHuangN, et al.Mucoadhesive poloxamer-based hydrogels for the release of HP-β-CD-Complexed dexamethasone in the treatment of buccal diseases. Pharmaceutics2021; 13: 117.
50.
ZhouHYZhangYPZhangWF, et al.Biocompatibility and characteristics of injectable chitosan-based thermosensitive hydrogel for drug delivery. Carbohydr Polym2011; 83: 1643–1651.
51.
GrecoIMolchanovaNHolmedalE, et al.Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides. Sci Rep2020; 10: 13206.
52.
OkamotoYOhkoshiKItagakiH, et al.Interlaboratory validation of the in vitro eye irritation tests for cosmetic ingredients. (3) evaluation of the haemolysis test. Toxicol Vitro1999; 13: 115–124.
53.
Antonia MurilloGTurEVinardellMP, et al.José Ramón Pascual. Ocular irritation assessed in vitro by a hemolysis and hemoglobin denaturation test. Revista de Toxicologia2003; 20: 193–198.
54.
NayakKMisraM. Triamcinolone acetonide-loaded PEGylated microemulsion for the posterior segment of eye. ACS Omega2020; 5: 7928–7939.
55.
ThangNHChienTBCuongDX. Polymer-based hydrogels applied in drug delivery: an overview. Gels2023; 9: 523.
56.
ChenWLiZHuJ, et al.Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS One2011; 6: e26103.
57.
WenQTrokelSLKimM, et al.Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations. Cornea2013; 32: 179–184.
58.
BursteinNL. Preservative alteration of corneal permeability in humans and rabbits. Investig Ophthalmol Vis Sci1984; 25: 1453–1457.
59.
Burek-MichalskaATurno-KręcickaA. Adalimumab in the treatment of non-infectious uveitis. Adv Clin Exp Med2020; 29: 1231–1236.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
